20250324-招银国际-讯飞医疗科技-02506.HK-Leading_the_healthcare_AI_revolution__Initiate_with_BUY_6页_1018kb

Xunfei Healthcare (2506 HK) Summary

Core Content

Xunfei Healthcare is a leading player in China's healthcare AI market, with a market share of 5.9% in 2023. The company is at the forefront of the healthcare AI revolution, leveraging its Spark Medical Model and strategic partnerships to enhance medical services across primary healthcare (PHC), hospitals (B), patients (C), and regional administrators (G).

The company is initiating coverage with a BUY rating and a Target Price (TP) of HK$170.56, based on a 13x 2026E P/S multiple. This reflects strong growth expectations and the potential for the company to significantly narrow its net losses.

Market Outlook

• Healthcare AI Market Growth: China's healthcare AI market is expected to grow from RMB8.8bn in 2023 to RMB315.7bn in 2033E, with a CAGR of 43.1%. This growth is fueled by favorable policies and the increasing adoption of AI in healthcare institutions.
• Revenue Growth: Xunfei Healthcare's revenue is projected to grow at a CAGR of 36.9% from 2023 to 2026E, with forecasts showing:
  • 2024E: RMB725 million
  • 2025E: RMB1,020 million
  • 2026E: RMB1,427 million

Business Segments and Performance

PHC Services

• 2024E: RMB231 million (-3.8% YoY)
• 2025E: RMB265 million (+15.0% YoY)
• 2026E: RMB292 million (+10.0% YoY)

Hospital Services (B-end)

• 2024E: RMB133 million (+104.7% YoY)
• 2025E: RMB226 million (+70.0% YoY)
• 2026E: RMB373 million (+65.0% YoY)

Patient Services (C-end)

• 2024E: RMB251 million (+86.5% YoY)
• 2025E: RMB402 million (+60.0% YoY)
• 2026E: RMB623 million (+55.0% YoY)

Regional Healthcare Solutions (G-end)

• 2024E: RMB110 million (-5.6% YoY)
• 2025E: RMB127 million (+15.0% YoY)
• 2026E: RMB139 million (+10.0% YoY)

Key Strengths

• Technological Backing: The company benefits from the advanced foundational AI model capabilities of iFlytek, a key shareholder.
• B2B and B2C Growth: Strong expansion in both B2B (hospital services) and B2C (patient services) segments has driven significant revenue increases, particularly in 1H24, where hospital and patient service revenue surged by 146% YoY, contributing 66.9% of total revenue.
• Product Innovation: The launch of Spark Medical Model X1 in March 2025 demonstrated superior performance in key medical reasoning tasks compared to GPT-4o and DeepSeek R1.
• Strategic Partnerships: The company continues to build a robust ecosystem through B2B partnerships, enhancing its commercial channel barriers.

Financial Highlights

Investment Risks

• Regional Expansion: Potential underperformance in expanding to new markets.
• Macroeconomic Factors: Impact of economic downturns on hospital procurement.
• Demand Fluctuations: Weaker-than-expected demand for AI healthcare solutions.
• Intensified Competition: Increased competition in the healthcare AI sector may affect market share and profitability.

Peer Comparison

Valuation and Growth

• P/S (2026E): 10.3x
• P/B (2026E): 15.5x
• CAGR (2023-2026E): 36.9%
• Net Loss Narrowing: The company is expected to significantly narrow its net losses over the forecast period.

Analysts and Contact

• Analysts: Jill WU, CFA; Cathy WANG
• Contact Info:
  • Jill WU: (852) 3900 0842; jillwu@cmbi.com.hk
  • Cathy WANG: (852) 3916 1729; cathywang@cmbi.com.hk

Important Disclosures

• The information in this report is not tailored to individual investors and is for general informational purposes only.
• CMBIGM does not guarantee the accuracy or completeness of the data.
• The report may not be reproduced or distributed without prior written consent.

CMBIGM Ratings

• BUY: Potential return of over 15% over the next 12 months.
• HOLD: Potential return of +15% to -10% over the next 12 months.
• SELL: Potential loss of over 10% over the next 12 months.

This summary captures the essential details of Xunfei Healthcare's position in the healthcare AI market, financial performance, growth prospects, and associated risks.